OMER - Omeros Corporation
| Previous Close | 14.35 |
| Open | 14.34 |
| Bid | 11.00 x 100 |
| Ask | 15.13 x 500 |
| Day's Range | 13.66 - 14.53 |
| 52 Week Range | 8.36 - 27.09 |
| Volume | 1,249,529 |
| Avg. Volume | 1,447,740 |
| Market Cap | 662.484M |
| Beta | 3.66 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.17 |
| Earnings Date | May 8, 2018 - May 14, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 36.20 |
- GlobeNewswire•7 days ago
Research Report Identifies T. Rowe Price Group, Omeros, Old Dominion Freight Line, Dillard's, BGC Partners, and Rexnord with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
NEW YORK, April 19, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
- Business Wire•7 days ago
Additional Clinical Studies Supporting the Benefits of OMIDRIA® Presented at the American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual Meeting
Omeros Corporation announced that the results of four real-world clinical studies evaluating the benefits of OMIDRIA® 1% / 0.3% were presented at the American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual Meeting held in Washington, D.C., April 13-17, 2018.
- Business Wire•13 days ago
Omeros Corporation Announces Upcoming Presentations of New Data on OMIDRIA® at the American Society of Cataract and Refractive Surgery Meeting
Omeros Corporation today announced that the results of four studies directed to the benefits of OMIDRIA across a range of clinical situations in cataract surgery will be presented at the upcoming American Society of Cataract and Refractive Surgery Congress in Washington, D.C., April 13-17, 2018.
- Business Wire•14 days ago
OMIDRIA® Added to Veterans Health Administration National Formulary
Omeros Corporation today announced that the Veterans Administration has added OMIDRIA® to the VA National Formulary.
- Market Realist•15 days ago
Why Omeros Stock Rose Last Week
In December 2017, the FDA approved Omeros’s supplemental new drug application for expanding the use of Omidria for pediatric use. Omidria prevents intraoperative miosis and also reduces post-operative pain for individuals undergoing cataract surgery and intraocular lens replacement. In January 2018, the European Medicines Agency’s Committee for Orphan Medicinal Products responded positively to Omeros’s application for orphan drug status for OMS721 for the treatment of primary immunoglobulin A nephropathy.
- Business Wire•15 days ago
Omeros Announces Amendment of Credit Facility
Omeros Corporation today announced that it has entered into an amendment to its existing credit facility with certain affiliates of CRG LP, a healthcare-focused investment firm.
- Simply Wall St.•22 days ago
What Should Investors Know About Omeros Corporation’s (NASDAQ:OMER) Growth?
Omeros Corporation’s (NASDAQ:OMER) announced its latest earnings update in December 2017, which signalled that losses became smaller relative to the prrior year’s level – great news for investors Below, I’veRead More...
- Market Realist•28 days ago
Why Omeros’s Revenue Surged
Omeros (OMER) generated total revenue of $64.8 million in fiscal 2017, compared with $41.6 million in fiscal 2016. Between fiscal 2016 and fiscal 2017, Omeros’s product sale costs fell to $1 million from $1.4 million, and its SG&A (selling, general and administrative expenses) rose to $52 million from $43.7 million.
- Market Realist•28 days ago
A Look at Omeros’s Promising Research Pipeline
An Investor's Overview of Omeros
- Market Realist•28 days ago
Analysts’ Ratings for Omeros and Peers in March 2018
An Investor's Overview of OmerosCompany overview
- Benzinga•last month
Omeros, Mattel, And 3 Other Stocks In Clear Trending Patterns This Week
In light of Monday's volatility, here are five stocks to watch this week according to VantagePoint , a platform that uses artificial intelligence and Intermarket analysis to predict price movement. What's ...
- Benzinga•last month
ICYMI: GameStop, Omeros, Congress Impacts Biotechs
In case you missed it, here are some of Benzinga's top stories from Thursday, March 22, 2018. GameStop’s Turnaround Progress With GameStop Corp (NYSE: GME ) reporting its Q4 results next week, analysts ...
- TheStreet.com•last month
New Budget Deals Big Pharma a Blow on Medicare Part D, but Omeros Scores
Despite lobbying hard for changes, the pharmaceutical industry is going to cover more costs regarding Medicare Part D in the $1.3 trillion budget that needs to pass by Friday.
- Motley Fool•last month
Why Lands' End, Omeros, and MGP Ingredients Jumped Today
Learn how these stocks kept from falling with the market.
- Benzinga•last month
Omeros Elevated By Medicare Reimbursement And OMS721 Progress, Says Maxim
Extended Medicare reimbursement for Omeros Corporation (NASDAQ: OMER )’s OMIDRIA , along with the company’s increased focus on OMS721 trials, will act as solid short- and long-term drivers, according to ...
- Motley Fool•last month
Here's Why Omeros Corporation Is Bouncing Back Today
A few pages in a gigantic spending bill could allow the Omidria train to start rolling again.
- Benzinga•last month
Biotech Winners And Losers From Congress' Latest Funding Bill
Congress introduced the Consolidated Appropriations Act of 2018 on Wednesday, and the bill contains fewer health care provisions than many traders expected. Still, Height Capital Markets analyst Andrea ...
- MarketWatch•last month
Omeros shares surge 45% on spending bill that benefits its drug
Omeros Corp. shares surged 45% in extremely heavy morning trade Thursday on a new government spending bill that benefits its cataract surgery drug Omidria. Omidria's "pass-through" status with ...
- Simply Wall St.•last month
Omeros Corporation (NASDAQ:OMER): Is Breakeven Near?
Omeros Corporation’s (NASDAQ:OMER): Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. TheRead More...
- Benzinga•last month
Benzinga Pro's 5 Stocks To Watch Today
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Guess?, Inc. (NYSE: GES ) stock gained more than 11 ...
- Motley Fool•2 months ago
Is Omeros Corporation a Buy on the Dip?
This biotech's annual report contained some frightening news, but how bad is it?
- ACCESSWIRE•2 months ago
Today’s Research Reports on Trending Tickers: Omeros and Opko Health
NEW YORK, NY / ACCESSWIRE / March 2, 2018 / Markets continued to slide Thursday after President Trump announced that tariffs on steel and aluminum imports were on the way. The Dow Jones Industrial Average ...
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of OMER earnings conference call or presentation 1-Mar-18 9:30pm GMT
Q4 2017 Omeros Corp Earnings Call
- Associated Press•2 months ago
Omeros reports 4Q loss
On a per-share basis, the Seattle-based company said it had a loss of 34 cents. Losses, adjusted for non-recurring costs, came to 25 cents per share. The drug developer posted revenue of $13.8 million ...
